| Names | |
|---|---|
| Preferred IUPAC name | Sodium 2-[(2,6-dichlorophenyl)amino]phenylacetate |
| Other names | Voltaren Cataflam Pennsaid Solaraze Zipsor Flector Zorvolex |
| Pronunciation | /daɪˈkloʊ.fəˌnæk ˈsoʊ.di.əm/ |
| Identifiers | |
| CAS Number | 15307-79-6 |
| Beilstein Reference | 136496 |
| ChEBI | CHEBI:50181 |
| ChEMBL | CHEMBL1433 |
| ChemSpider | 5799 |
| DrugBank | DB00586 |
| ECHA InfoCard | 100.023.340 |
| EC Number | EC 233-432-5 |
| Gmelin Reference | 135131 |
| KEGG | D07816 |
| MeSH | D006449 |
| PubChem CID | 3033 |
| RTECS number | HE5850000 |
| UNII | W6SJM0E5PC |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C14H10Cl2NNaO2 |
| Molar mass | 318.13 g/mol |
| Appearance | White or almost white, crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Freely soluble in water |
| log P | 4.51 |
| Vapor pressure | <0.0000001 mmHg (25°C) |
| Acidity (pKa) | pKa = 4.0 |
| Basicity (pKb) | pKb = 9.33 |
| Magnetic susceptibility (χ) | -66.4 × 10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.572 |
| Dipole moment | 2.81 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 576.8 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -447.8 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -5234 kJ/mol |
| Pharmacology | |
| ATC code | M01AB05 |
| Hazards | |
| Main hazards | Harmful if swallowed, causes serious eye irritation, may cause allergic skin reaction. |
| GHS labelling | **"Danger; H315, H319, H335; P261, P264, P271, P280, P305+P351+P338, P405, P501"** |
| Pictograms | GI bleeding, GI ulcer, Asthma, Renal impairment, Hepatic impairment, Cardiovascular risk, Pregnancy risk, Skin reactions |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. Avoid contact with eyes, mucous membranes, or rashes. Do not use on wounds or damaged skin. Do not bandage tightly or use with a heating pad. |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | 113°C |
| Autoignition temperature | 250°C |
| Lethal dose or concentration | LD50 (oral, rat): 55 mg/kg |
| LD50 (median dose) | LD50 (median dose): 55 mg/kg (oral, rat) |
| NIOSH | SA150 |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | 100 mg daily |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds | Aceclofenac Aminophenazone Bromfenac Diflunisal Etodolac Fenamate Indomethacin Ketoprofen Meclofenamic acid Nabumetone Sulindac Tolmetin |
| Parameter | Details | Manufacturer’s Technical Notes |
|---|---|---|
| Product Name | Diclofenac Sodium | Referred to in batch records and QA documentation as Diclofenac Sodium. All label references match with regulated nomenclature for international trade and pharmacopoeia standards. |
| IUPAC Name | Sodium 2-[(2,6-dichlorophenyl)amino]phenylacetate | IUPAC name is used in specification documents and compliance certificates to align with pharmacopoeia and REACH requirements. Reflects the precise molecular structure for regulatory submission and substance registration purposes. |
| Chemical Formula | C14H10Cl2NNaO2 | Consistent with all analytical confirmation steps in production. Molecular formula informs elemental analysis and identity verification processes during quality control analysis. |
| Synonyms & Trade Names | Voltaren Sodium, Diclofenacum Natricum, Diclonac Sodium Salt | Synonym selection follows established pharmacopeial sources and export documentation protocols. Trade names vary by region and customer, subject to permissible use under trademark agreements and regulatory acceptance in specific destinations. |
| HS Code & Customs Classification | 2933.39 | HS Code assignment based on harmonized system schedule for nitrogen-function compounds. Customs coding is verified for each export consignment, and any regional sub-classification or regulatory import status is checked with forwarders and in-house trade compliance teams. Reclassifications may be necessary for formulated products or blends containing Diclofenac Sodium as an active ingredient. |
Production involves stagewise synthesis from 2,6-dichloroaniline and monochloroacetic acid, with each batch requiring strict control of impurity profiles, especially chlorinated by-products and residual solvents. Raw material batches are selected based on impurity scan and origin documentation, as off-spec batches can impact downstream solubility and API release profile. Process route selection (solvent route, microemulsion technique, or salt condensation) is typically linked to scale, desired impurity clearance, and final particle morphology required for customer application (e.g., pharmaceutical, veterinary, or formulated topical dosage).
Batch process steps include controlled chlorination and alkylation stages. In-process controls involve constant reaction pH and endpoint purity check before sodium salt conversion. Chromatographic analysis focuses on distinguishing positional isomers, solvent residues, and regulated trace contaminants. Process water and solvent recycling add complexity to contamination management.
Final Diclofenac Sodium purity, particle size, and moisture are grade-dependent and application-driven—oral solid dose producers require specific PSD ranges, parenteral grades require ultra-low bioburden thresholds, and topical grades often receive secondary milling or granulation. Batch consistency management employs statistical trending on purity, micro, and physical parameters to maintain process capability over time.
Release criteria are tied to both compendial standards (USP, EP, JP) and tailored customer quality agreements. Typical values for assay, impurity limits, residual solvents, and particle size distributions are aligned to each order or regulatory requirement. Any product distributed outside standard release parameters is segregated and reprocessed or downgraded, depending on internal risk assessment.
Commercial-grade diclofenac sodium typically appears as a white or light yellow crystalline powder. Off-the-shelf batches may vary slightly in hue depending on raw material purity. The material is odorless. Melting point is commonly referenced in pharmacopeial monographs for different grades; for pharmaceutical grade, the melting point normally aligns within the specified monograph range. Industrial grades for veterinary or technical formulation can demonstrate greater variability and may include minor polymorphic forms.
No appreciable boiling point; thermal degradation occurs before boiling. Decomposition may produce acrid fumes if overheated. Powder density and bulk flow characteristics vary with crystal form and particle size distribution, which are influenced by crystallization step and milling conditions during production.
Stability depends strongly on storage humidity, thermal exposure, and compatibility with formulation excipients. Diclofenac sodium exhibits higher stability under dry conditions. Moisture uptake can lead to hydrolysis and sodium salt degradation. Contact with strong acids reverts the salt to diclofenac acid, causing precipitation and possible loss of bioavailability in finished formulations.
Solubility in water is grade-dependent and affected by pH, temperature, and ionic strength of the diluent. Pharmaceutical grade calls for minimum solubility at neutral to alkaline pH; for analytical purposes, solutions are typically made in buffered media. In industrial granulation, solution concentration must consider saturation and precipitation risks at processing temperature. Insoluble residues highlight incomplete reaction or contamination during manufacture.
Final specification tables depend on end-use: pharmaceutical, veterinary, or technical. Pharmaceutical standard follows compendial monographs (USP, BP, EP) for identification, assay, and impurity limits. Veterinary and technical grades may allow wider impurity thresholds, subject to customer and regulatory requirements.
Typical impurity sources include incomplete reaction, raw material contaminants, or side-products from synthesis. Finished grade dictates allowable levels for each impurity class: residual solvents, related substances (such as 4-chlorodiphenylamine derivatives), and inorganic residues. Continuous monitoring of critical impurities forms part of the batch release process; precise thresholds remain confidential and specification-bound.
Routine batch release employs validated chromatographic (HPLC/GC) and spectrometric tests. Each testing program references both house-validated methods and official compendial procedures. Suitability tests include specificity for known impurities, calibration range, and reproducibility. The release standard always matches the grade and customer specification.
Key raw materials include 2,6-dichloroaniline and monochloroacetic acid, alongside sodium hydroxide for salt formation. Selection prioritizes traceability, impurity control in starting materials, and supplier reliability. Supply chain quality directly impacts impurity carryover; tight raw material specs reduce risk of non-conforming batches.
Production traditionally uses a two-step synthetic route: N-arylation of 2,6-dichloroaniline with monochloroacetic acid (or glycine) to give diclofenac acid, followed by neutralization with sodium hydroxide. Route selection balances process safety, waste minimization, and impurity minimization. Batch or continuous processes both see industrial use, depending on scale and regional labor costs.
Key control points include reaction temperature, pH, mixing rate, and crystallization conditions. Purification often employs recrystallization in alcohol-water mixtures to separate main product from colored organics and trace inorganics. Solvent choice and crystallization kinetics affect batch consistency and polymorph formation. Final product filtration and drying are controlled to target particle size and residual solvent specifications.
Every lot undergoes full release testing: visual inspection, identification, assay, impurity profiling, moisture content, and particle size. Out-of-spec batches are reprocessed, not blended. Batch-to-batch reproducibility is verified statistically over rolling production campaigns. Final release always meets customer-specific or pharmacopeial requirements.
Diclofenac sodium demonstrates moderate stability under acid and base catalysis; acid exposure leads to protonation and precipitation of the free acid, which can impact formulation in multi-component systems. It reacts with certain alkylating agents under laboratory conditions, though routine industrial modification is uncommon outside specialized API synthesis.
Salt formation favors aqueous or mixed aqueous-organic media, controlled alkaline pH, and moderate process temperatures to prevent thermal decomposition. Recrystallization may involve graded ethanol or isopropanol to maximize purity and yield.
Most derivative development focuses on salt forms for improved dissolution or modification of release profile in finished pharmaceuticals. Esterification or amidation is explored in research contexts but not deployed at industrial scale due to regulatory path complexity.
Proper storage requires low humidity, ambient temperature, and limited light exposure. High moisture environments speed degradation by hydrolysis. Diclofenac sodium should be protected from acidic vapors and stored away from oxidizers.
Industry-standard containers include polyethylene-lined fiber drums and high-density polyethylene (HDPE) bottles or bags. Contact with glass and most plastics poses no issues under recommended conditions. Metal packaging not recommended due to risk of corrosion or contamination.
Official shelf life information depends on product grade and packaging type. Typical degradation signs include discoloration, odor development, or visible particulate formation—these indicate hydrolysis or contamination. Regular monitoring of key quality attributes is mandatory, especially for pharmaceutical and regulated veterinary applications.
GHS hazard classification depends on regional regulatory reviews and can differ by jurisdiction. Diclofenac sodium is generally regarded as hazardous for ingestion and skin contact; specific hazard codes tied to local SDS and product grade.
Risks arise from dust inhalation, ingestion, or skin/eye exposure. Handling operations require local exhaust ventilation, nitrile gloves, and protective eyewear. Spilled material is swept or vacuumed to avoid airborne particulates.
Toxicity reference values are anchored to published pharmacological and toxicological studies. The substance shows dose-dependent gastrointestinal, renal, and hepatic toxic potential. No data supports significant dermal absorption under industrial handling conditions.
Manufacturing sites enforce occupational exposure standards set by internal risk assessments, referencing ACGIH or relevant local authority guidelines when available. Personal protective equipment and engineering controls form the first line of defense. Training focuses on chronic and acute risk mitigation in bulk material processing.
Typical installed capacity for Diclofenac Sodium remains concentrated in major Asian and European manufacturing hubs. As a producer, output scales directly with API reactor allocation, filtration line uptime, and solvent recovery rates. Actual batch throughput hinges on grade purity targets and downstream drying constraints. Output flexibility decreases as technical grade rises; tighter impurity profiles require more frequent process pauses and stricter in-process monitoring. The final stock available for delivery reflects operational yield after full QC release. Extended unplanned maintenance shutdowns or atypical quality deviations often limit short-term availability, affecting the commitment window for large-volume orders.
Across standard commercial grades of Diclofenac Sodium, lead times usually center around current campaign planning. For standard USP/EP/IP grades, lead time reflects vessel charging through validated purification and QA release, not off-the-shelf logistics. MOQ directly links to both campaign size and the pack size chosen; larger MOQs allow tighter batch run management but depend on the customer's regulatory and documentation needs. For high-purity or niche formulations, MOQ may reflect campaign exclusivity or specific customer validation protocols.
Packaging moves from HDPE drums for bulk pharmaceutical orders to tamper-evident, double-lined bags for sensitive applications. Pharmaceutical grade requires inert liners to avoid contamination and protect from hydrolysis. Custom pack sizes often center on dosage manufacturer demand and equipment fit—higher grades may involve unit-dose packing under inert atmosphere or with certified traceability seals.
Shipping methods reflect destination risk, temperature sensitivity, and regulatory clearance. Air freight dominates urgent clinical deliveries but faces stricter documentation checks. Standard commercial contracts utilize LC or TT payment terms, often subject to project-specific credit evaluation. Delivery conditions conform to Incoterms, with insurance or customs handling varying by destination country risk profile. Documented batch traceability accompanies each shipment, satisfying pharmaceutical regulatory audits.
Diclofenac Sodium production draws cost influences from both direct chemical precursors and energy-intensive process steps. Base cost structure aligns with upstream access to aniline derivatives, ortho-chloroacetic acid, and solvent system prices. Upstream volatility—driven by crude oil market swings or chlorination reagent price spikes—transfers directly into monthly contract quotes. Process route selection—solvent-based versus water-mediated syntheses—can shift raw material weights by 8–15%, with energy efficiency improvements and waste minimization strategies offering cost buffer over time.
Supply bottlenecks often stem from export restrictions, unforeseen global disruptions, or batch quality rejections. Regulatory announcements impacting key excipient or precursor approvals can push price surges across a fiscal quarter.
Pricing splits by grade: pharmaceutical grade commands higher prices than technical grades due to stricter release criteria and regulatory-mandated documentation. Further splits arise based on defined impurity thresholds and analytical method validation (HPLC/GC), driving price step changes between generic and originator-equivalent product. Purity above regulatory baseline increases synthesis complexity and rejection risk, requiring extra purification passes, thus raising cost per kilo.
Certification—including GMP, DMF-registered, or EU-FMD batch-level traceability—is non-negotiable for international pharma supply and reflects in cost escalation. Bulk packs lower per-kilo handling cost, but small clinical trial batches—especially custom-certified—carry higher relative cost burden.
Demand centers on established pain and anti-inflammatory indications, with Asia and Latin America sustaining volume growth while regulatory tightening in North America and EU enforces stricter supply screening. Capacity in China and India presents the largest global output share, with periodic shutdowns or GMP inspections affecting visible supply. EU, US, and Japan maintain higher pricing brackets tied to regulatory compliance costs and local batch release hurdles.
| Region | Capacity Situation | Regulatory Demands | Price Sensitivity |
|---|---|---|---|
| US | Heavily reliant on imports, limited domestic capacity. | USP monograph, DMF-required, routine FDA inspections. | Premium on DMF-registered supply and track/trace compliance. |
| EU | Balanced local and import supply, stringent audits. | EDQM/CEP, FMD compliance, import batch re-testing protocols. | Pricing reflects dual documentation and traceability costs. |
| JP | Tight control, limited domestic API production. | JP Pharmacopoeia, local agent representation, site audits. | Imports need extensive validation, raising landed cost. |
| IN/CN | Large installed base, export-oriented. | Local GMP, growing compliance with PIC/S harmonization. | Cost competitive on technical/standard pharma grade, price moves with raw input volatility. |
By 2026, expected API contract prices for regulated markets track incremental upward pressure from global supply chain instability, enhanced GMP enforcement, and upstream input volatility. Emerging market demand and selective local regulatory tightening create a fragmented landscape. Price resilience grows with grade and documentation requirements, while technical-grade supply stabilizes if raw precursor markets avoid major disruptions. Data draws from proprietary production trend records, public customs statistics, and national regulatory filings.
Production and pricing data reflect internal batch campaign logs, customer shipment records, regional customs data, and regulatory agency bulletins. Trend forecasts blend internal operations planning, major commodity chemical price indices, and observable tender outcomes.
Recent detection of off-spec impurity loads in several API consignments out of Southeast Asia triggered regulatory scrutiny of solvent waste handling protocols. Larger manufacturers shifted focus to in-line monitoring and process traceability, with added documentation steps for EU and US-bound batches.
Increasing frequency of joint agency audits across India and China drove facility upgrades and process mapping realignment. Expanded interpretation of nitrosamine risk by several authorities raised the bar for cross-contamination controls, requiring documented analytical method updates and batch-level reports.
Production facilities adopted phase-by-phase process audits and batch genealogy mapping to satisfy evolving import compliance standards. Investments in validated cleaning verification, robust deviation log documentation, and expanded in-process sampling reduced both rejection rates and recall risks. Risk-sharing arrangements for raw material volatility with contract customers gained traction, ensuring more transparent and adaptable supply agreements.
Diclofenac Sodium serves primarily in pharmaceutical and veterinary preparations. The production department frequently encounters requirements distinct between human medicinal formulations and topical veterinary use. Most inquiries focus on API-grade material for solid oral dose formulation, topical gel manufacturing, and injectable solutions. Some industrial segments also request technical grades for research, reference standards, or non-pharma intermediates.
| Application | Typical Grade | Peculiar Requirements |
|---|---|---|
| Human Pharmaceutical (Oral/Injectable) | Pharmaceutical (API, USP/EP/JP grade) | Absolute focus on purity, traceability, and compliance to pharmacopoeial monographs; low organic/elemental impurities, GMP compliance, batch documentation |
| Veterinary Pharmaceutical | Veterinary API grade | Purity standards often adapted to regional regulations; documentation often tailored for animal use; attention to specific by-product profiles |
| Topical/External Use | API (Pharma or Veterinary) or Cosmetic Ingredient Grade | Microbial control and residual solvent profile receive heavier scrutiny |
| Research & Analytical | Reference or Research Grade | Strict lot traceability, characterization data, and batch history records provided |
Pharmaceutical products for human use lead to the highest benchmark for chemical purity, identity, and regulatory paperwork. Veterinary markets and research users flag different priorities: analytical confirmation, flexibility in documentation, or specific secondary impurity awareness.
The production and QA departments confirm destination country and intended use early in discussion. Final grade determination occurs only after confirmation of whether US, European, Japanese, or other jurisdictional pharmacopeia lists apply, or if a local standard guides batch release. Policies on DMF support, audit rights, and quality agreements enter at this stage.
Clients set boundary conditions for purity, but batch-to-batch analytical data drives the process department to adjust parameters. Typical values depend on process history, but deliberate modification of crystallization and purification strictly follows end-use constraints. Certain applications require detailed impurity profiles before shipment authorization. These profiles are grade-dependent and must be adapted for client-supplied methods if necessary.
Large-scale, high-purity batches introduce downstream cost considerations, as HPLC-based purification and sterile filtration steps vary with order size. Pilot-scale production can precede commercial batch manufacturing when volumes justify additional QA verifications or customer audits. Bulk packing choices, intermediate hold times, and logistics strategies reviewed in direct coordination with buyer requirements. Budget and lot size impact whether continuous or batch processing is appropriate for the production plan.
Sample requests enable real-world validation of manufacturing claims. The technical team recommends evaluation of production-scale representative samples before first commercial order. Customer feedback informs any necessary adjustment at the process or packaging stage. Final release follows signed-off internal and external validation criteria, with product trailable back to source batch documentation.
At our production site, the quality management framework draws on internationally recognized standards, including adherence to ISO 9001 for quality systems and ISO 14001 for environmental management where required by downstream partners. Certification involves annual internal audits, detailed document control, and ongoing management review of process risk, deviation traceability, and customer feedback. For pharmaceuticals and veterinary grade Diclofenac Sodium, our site maintains additional QMS protocols in line with GMP or equivalent national frameworks upon request.
QMS traceability extends from raw material batch selection to in-process quality gates and final release for each manufacturing campaign. End-user industries, such as pharmaceutical formulation or animal health, often require supplementary QMS documentation or validation support. These requests are managed through structured change control and customer audit programs.
Diclofenac Sodium produced in our facility can attain compliance with pharmacopoeial standards, which may include USP, EP, IP, or other recognized monograph requirements. Actual certificates (CoA, CoC, GMP, MOH approvals) reflect process route, batch size, and intended regulatory jurisdiction. Certification is grade-dependent and reflects both final testing and process validation data relevant to each production lot.
Regional regulatory approvals alter traceability requirements and documentation depth. For example, veterinary versus human pharmaceutical applications will engage distinct certification pathways and reporting structures. Product grades tailored for industrial non-pharma use follow internal quality release standards, subject to industry-specific agreement.
Routine documentation includes batch-specific Certificates of Analysis, detailed process records, impurity profile reports, raw material lot tracking, and relevant SDS. For regulatory submission or customer audit support, dossiers can include stability data, residual solvent panels, elemental impurity screening, and validated analytical method summaries. Document packages are cross-checked by product release teams before dispatch.
Access to detailed records beyond standard CoA or SDS, such as qualification protocols or validation summaries, is coordinated directly with the customer’s technical or regulatory teams. The extent of documentation support correlates to product application and customer compliance protocol, especially where end-use registration or advanced QbD documentation is needed.
Core production facilities operate long campaign scheduling for pharmaceutical-grade Diclofenac Sodium, with planned maintenance windows coordinated around customer forecasts. Production lots are deliberately structured for both large-scale and niche batch supply. Customers operating under variable demand cycles often require laddered delivery schedules or consignment stock solutions. Planning integrates forecast-adjusted production cycles, linked directly to order intake and safety stock buffers at the finished goods warehouse.
Business cooperation extends beyond supply commitments. Project-based engagements involving formulation changes, regulatory expansion, or technical transfer rely on direct technical team collaboration to align production capability with downstream launch schedules. Flexible contract structures can include fixed price, indexed price, minimum order commitment, or rolling call-off models. These options are calibrated against raw material indexation, utility consumption patterns, and customer risk-sharing interests.
Core production lines are designed for multi-grade flexibility, allowing streamlined shift between pharmaceutical and veterinary grades through validated cleaning and changeover protocols. Mechanical isolation, process validation checks, and continuous parameter logging form the backbone of run-to-release verification. Lot size selection is application-driven, with bulk campaigns prioritized for stable annual contracts and small-scale runs aligned with specialty or developmental project needs.
Process and capacity adjustments follow customer demand signals managed through rolling forecast mechanisms. Production slotting is fixed no later than six to eight weeks before dispatch, with cut-off for expedited slots dependent on current process load and planned campaign window. For customers in regions with import restrictions or extended lead times, parallel finished-goods staging enables risk-mitigated supply.
Sample quantities, available by application and intended end use, are prepared under controlled conditions. Pharmaceutical-grade or regulatory-critical samples undergo full batch sampling with CoA and supplementary analytical reports. Requests for samples should include target grade, use scenario, and any analytical or documentation expectations; this ensures samples reflect real use cases. All sample shipments follow site QA approval and are logged for traceability.
Requests from formulation development or registration teams sometimes necessitate technical dossiers, material safety evaluation, or validation support. Sample dispatch aligns with customer project timelines to support technical evaluation, qualification, or regulatory submission phases.
We adapt supply models based on customer production cycles, regulatory timelines, and inventory management preferences. Firm contract deliveries, rolling call-off orders, and VMI (Vendor Managed Inventory) approaches are discussed with concerned stakeholders to ensure continuity through supply chain disruptions. For demanding or volatile markets, buffer stock or priority production capacity can be reserved under specific agreement.
Long-term partners benefit from integrated development and supply planning, where technical and commercial teams coordinate to manage supply risks, shift supply modes for project launches, or implement controlled phase-ins of updated process routes. Collaboration includes regular joint review of production forecasts, logistics lead times, and regulatory status changes. This enables prompt adjustment to specification changes, compliance upgrades, or new customer project timelines.
Research in diclofenac sodium focuses on improved synthetic process efficiency, strategies for lowering hazardous byproducts, and methods to reduce residual solvent residues in the final API. Industrial teams target optimization of solvent recovery cycles, improved yield by catalyst selection, and robust impurity profiling. Raw material traceability receives increased scrutiny due to market-driven demand for consistent batch reproducibility. Grade-specific adjustments in crystallization and filtration steps address different downstream formulation needs, ranging from immediate-release tablets to sustained-release systems.
Development continues for topical and transdermal systems, driven by interest in minimizing systemic exposure. Veterinary applications see adjustments in purity profiles and particle size distribution to optimize animal health product performance. There is industrial interest in fine-tuning salt forms for better solubility and novel delivery vehicle compatibility. R&D also examines excipient interactions, notably with co-processed carriers and stabilizers, that alter stability during long-term storage or after formulation blending.
Batches can exhibit variable polymorphic composition based on solvent ratios and temperature profiles, making in-process analytical testing essential for commercial manufacture. Process engineers frequently contend with the generation of trace-level nitrosamine impurities. Implementation of real-time monitoring, using PAT tools, shortens deviation response times. Breakthroughs in impurity isolation and identification, achieved by high-resolution chromatography, support regulatory filings and process validation for regulated markets.
Global demand for NSAIDs, including diclofenac sodium, depends on drug policy developments, generic penetration rates, and emerging market expansion. Procurement teams observe shifting raw material sourcing patterns, especially for precursor chemicals and APIs from Asia and Europe. Customers increasingly request grade-specific documentation for both regulatory and downstream audit purposes. Regional volatility in supply chain logistics remains a challenge, with risk mitigation handled by multi-source supplier strategies and increased contract manufacturing partnerships.
Synthesis routes trend towards lower environmental impact via reduction of chlorinated solvents and reliance on milder reagents. Automated process control continually replaces manual intervention, with data logging facilitating root-cause analysis of out-of-specification events. Renewed interest in green chemistry pushes continuous processing and aqueous-phase crystallization, reducing waste production and energy input. Equipment upgrades, such as improved centrifuge technologies, address batch-to-batch moisture variation that can affect downstream blending. Manufacturing adapts to regulatory and client-driven requirements by refining in-process control points to ensure both API compliance and fit-for-formulation endpoints.
Process chemists replace legacy reagents with greener alternatives whenever possible. Solvent recycling systems form part of standard plant design, although degree of recovery depends on product grade required and solvent compatibility. Waste treatment strategies focus on minimizing halogenated organic discharge. Production lines deploy continuous quality monitoring to lower reprocessing rates, conserving energy and resources. Larger customers request environmental impact statements, and these reports are tailored based on both plant location and batch run specifics.
Technical support teams draw from direct production and QC experience to address customer formulation or compounding challenges. Consultation includes guidance on particle size adjustment, impact of specific excipients, and recommended lot selection for particular application types. Support uses real plant data to assist clients with change control management, stability troubleshooting, and transition between grades.
Application engineers provide batch-specific documentation and technical background on manufacturing adjustments for sustained-release or topical product requirements. Advisory services cover compatibility with alternative carriers, dissolution profile tuning, and guidance on in-plant granulation processes, pulling directly from manufacturing logs and post-marketing surveillance.
After-sales service includes lot-specific analytical report availability, collaborative deviation investigations, and proactive updates in response to evolving regulatory guidance. Product traceability and root-cause analysis are standard, driven by batch records, impurity monitoring, and production batch history. Technical feedback loops with customers facilitate continual process improvement, with dedicated teams ensuring that downstream performance requirements—such as blending, tableting, and long-term stability—are met consistently.
Our production facility manufactures Diclofenac Sodium at industrial scale for the global pharmaceutical, veterinary, and specialty chemical sectors. The process uses advanced synthesis pathways and proprietary purification technology to deliver high assay material fit for use in complex downstream formulations. Our plant controls each phase — from raw material selection through in-house reaction monitoring — to maintain predictable output.
Diclofenac Sodium from our lines primarily serves as an active pharmaceutical ingredient for oral and topical non-steroidal anti-inflammatory drug preparations. Commercial end users rely on this material for tableting, capsule filling, injectable solutions, and gel formation, especially in facilities demanding strict traceability for regulatory filing. In animal health, feed and veterinary product manufacturers select our product for its reproducible anti-inflammatory activity.
All production batches pass full analytical verification, including HPLC, IR, UV, and purity assessments. We control impurity profiles to meet required pharmacopeial standards. Batch-to-batch reproducibility remains a core benchmark. Each shipment includes quality certificates prepared by our own laboratory team, with retention samples kept for the full archive life. This model allows us to ensure that each load matches published specifications and regulatory dossiers.
Our packaging systems handle everything from small pilot-scale bags to 25 kg fiber drums and palletized full-container quantities. Materials undergo nitrogen purging and double-bagging to control moisture pickup and contamination risk. Every order runs under a stable supply program defined in our own logistics portal, giving us control over lead times, labeling, and custom packaging options to fit high-volume commercial runs.
Our technical service team supports buyers during process changes, scale-up, and method validation. We collaborate with manufacturing engineers, quality assurance managers, and laboratory chemists to optimize the product’s incorporation into formulations and address regulatory filing tasks. Our documentation package covers full traceability, regulatory compliance data, and stability support for product lifecycle planning.
Direct relationships with our facility provide customer companies clarity on manufacturing control, lot traceability, and supply availability. Shifting procurement from indirect sources to direct manufacturing unlocks consistent scheduling and lowers risk of supply chain interruption. Our operation offers industrial buyers transparency on quality regimes and production timelines, critical for those managing regulated workflows or coordinating with multiple contract partners in the pharmaceutical sector.
| Parameter | Our Production Oversight |
|---|---|
| Batch Consistency | Monitored by real-time analytical controls onsite |
| Packaging | Direct packing with controlled atmosphere and integrity checks |
| Documentation | In-house COA, regulatory statements, batch retention |
| Delivery Model | Scheduled bulk or customized runs through plant dispatch |
| Technical Interaction | Formulation troubleshooting, process validation, support for industrial clients |
Day-to-day operations focus on manufacturing reliability, end-use fit, and responsive technical backup, providing a credible foundation for buyers across pharmaceutical and veterinary sectors who require secure, well-documented supply of Diclofenac Sodium at scale.
In large-scale production of diclofenac sodium, our team stays focused on its core pharmacological properties. Years of manufacturing experience ground our understanding of its clinical significance and guide our quality control. As a non-steroidal anti-inflammatory drug, diclofenac sodium holds value because it consistently demonstrates reliable inhibition of the cyclooxygenase (COX) enzyme, which plays a key role in pro-inflammatory mediator synthesis.
From raw synthesis to the final API, we see firsthand how diclofenac’s molecular structure enables the selective inhibition of COX-2 over COX-1. This selectivity stems from the sodium salt of diclofenac, which blocks the conversion of arachidonic acid to prostaglandins. Less prostaglandin synthesis means reduced inflammation, analgesia, and antipyretic effects. This is not just textbook knowledge—batch consistency and purity directly affect these outcomes. Our R&D group continually monitors the specific activity and impurity profile of each production lot because even small variations can change the therapeutic profile and tolerability of the finished drug product.
In oral formulations, absorption is rapid and largely complete, though first-pass hepatic metabolism reduces systemic bioavailability. This factor guides our choice of excipients and granulation technique during production of the API and finished product. The peak plasma concentration typically appears within two to three hours after administration. Diclofenac sodium displays high protein binding, which we routinely verify by testing as part of in-process QC protocols.
Our technical team places great emphasis on ensuring the correct polymorphic form during crystallization, since this can impact solubility, absorption rate, and shelf-life. Consistency at this stage minimizes variability in patient response. After absorption, the compound undergoes extensive hepatic metabolism. More than 99% of metabolites are excreted in urine and bile, so residual solvents and by-products from manufacturing are rigorously removed to prevent any interference with patient metabolism.
Therapeutic efficacy depends not just on the molecule itself, but on tight control of every parameter that influences how the body handles the drug. We prioritize batch-to-batch consistency because variable pharmacokinetics can arise from subtle differences in particle size, morphology, or impurity content. Every production run incorporates full traceability of starting materials, and state-of-the-art instrumentation certifies each output meets our validated standards. Each lot undergoes full spectrum analysis for purity, dissolution, and polymorphic integrity prior to release.
Our customers rely on our expertise in the physical and chemical nuances of NSAID production. Our ability to deliver well-characterized, high-purity diclofenac sodium minimizes downstream development risks for finished dosage manufacturers. We maintain a transparent, compliant production process so end-users and formulators know exactly what to expect from every shipment. For technical documentation or additional details, our support team can provide full dossiers and batch-level analytics to partners in the pharmaceutical sector.
Diclofenac Sodium stands as one of our core pharmaceutical actives, produced in-house under regulated conditions that align with prevailing international standards. Customers regularly ask about minimum order quantities and typical delivery schedules. Our aim is always to strike a balance between logistical efficiency and maintaining consistent supply for each partner.
Batch integrity and inventory control drive our approach to minimum order size. Orders under 25 kg rarely make practical sense from a production standpoint. Smaller lots increase material waste, strain packaging resources, and add to turnaround complexities. Bulk synthesis and downstream processing, from crystallization to drying and milling, are scaled for throughput, not low-volume lots. We designed our standard minimum order for most global shipments at 25 kilograms. This unit lets us consolidate warehousing, minimize deviation risk, and deliver a stable price structure for both parties. When a client has a demand beyond typical pack sizes, our team reviews production scheduling on a case-by-case basis.
Production planning requires attention to accurate forecasting, regulatory documentation, and up-to-date analytical testing. For most routine orders, our lead time sits between 2 to 4 weeks from confirmation. This window covers scheduled synthesis, drying, milling, QC release, and final packaging under GMP-compliant conditions. Custom requirements or documentary legalization can extend timelines. Advance notice often allows us to coordinate raw material procurement and reserve capacity, protecting downstream manufacturing for our clients. Emergent situations—such as pandemic-related spikes—may stretch timelines due to logistics bottlenecks outside the facility. Our operations team provides rolling updates during the fulfillment process to keep clients informed.
Each inquiry brings its own set of challenges. Unusual assay specifications or alternate packaging increase processing requirements and risk of scheduling overlap during peak season. Clients requiring specific particle sizes or micronization typically see an extension of lead time by several days, as these processes demand dedicated validation. Adhering to regional documentation or specific DMF requirements also plays into delivery timing. As the manufacturer, we remain transparent regarding scheduling constraints and production status, helping our customers align their inventory plans with realistic arrival windows. Repacking, alternative labeling, and export regulatory tasks always demand extra processing in our QA pipeline.
No two partners have the same needs. Our experience producing Diclofenac Sodium for global regulated markets gives us an edge in responding effectively to varied project timelines and order volumes. We communicate openly about the operational realities of primary manufacturing and packaging. This attitude supports reliability throughout the year and allows our customers to plan major production runs or new launches without facing uncertain inventories. Supporting long-term relationships means making our capacity forecast and scheduling transparent, building business continuity for both sides of the table. Our technical and commercial teams are available for direct, detailed consultation to help plan upcoming procurement cycles.
Diclofenac Sodium has attracted extensive regulatory scrutiny on a global scale. Regulatory agencies in many regions classify it as an active pharmaceutical ingredient that demands strict oversight, given its widespread use in both human and veterinary formulations. As the manufacturer, we spend significant effort aligning our operations with the legal framework of key markets, including the European Union, North America, the Middle East, and Asia Pacific.
Our finished Diclofenac Sodium is packaged and stored in controlled humidity environments with integrated temperature monitoring. We utilize sealed, inert-lined drums and double-layer polyethylene bags to protect the product from moisture uptake and contamination during storage and handling. Our warehouse maintains a clean, dry, and well-ventilated setup, with temperatures not exceeding 25°C. This helps avoid hydrolysis or degradation, which can trigger regulatory issues and invalidate entire lots.
We assign trained staff to oversee lot segregation. Each batch receives a unique code and independent documentation. Our personnel conduct regular inspections for any sign of caking, discoloration, or foreign particulate to ensure nothing compromises quality before orders leave our facility.
We print all required hazard information, best-before dates, and lot numbers directly on each drum or carton, following international labelling conventions. Languages and symbol formats adapt to destination country preferences, reducing the risk of customs delay or non-compliance fines.
Exporting Diclofenac Sodium brings added complexity compared to domestic sales. Customs in many regions demand import licenses, pre-shipment registration, and paperwork tracing every lot to our production logs. We work proactively with the import authorities of high-volume markets, providing certificates of analysis, GMP certificates, and full traceability. In the European Union, REACH restrictions and the API registration frameworks require an extra layer of documentation and, at times, local batch release testing before distribution can proceed.
The United States requires strict adherence to Drug Enforcement Administration and Food and Drug Administration requirements throughout the import process. We hold establishment registrations and provide Drug Master Files for clearance. For emerging markets and the Middle East, Ministry of Health import permits commonly require notarized documents and site audits prior to approval, extending lead times.
Transit conditions carry significant weight in compliance. We ship only with carriers qualified to handle pharmaceuticals, validated on Good Distribution Practices. Containers must remain sealed and protected from exposure. We install temperature loggers inside shipments when climatic risk is present, sharing these records directly with importers to support post-arrival inspection.
Regulations evolve as more authorities react to misuse or environmental impact from nonsteroidal anti-inflammatory drugs. We dedicate a compliance team to active monitoring, immediate update of our documentation, and regular audits of our facilities. Should a country update its restrictions or demand for eco-friendly handling, we integrate those standards directly into our production and export practices.
This focus on hands-on risk management, reliable documentation, and real operational transparency allows partners in every region to depend on our chemical consistently meeting international requirements for safety, storage, and lawful trade.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
